Benchmark Holdings PLC Market Authorisation Update (9826J)
May 03 2022 - 2:01AM
UK Regulatory
TIDMBMK
RNS Number : 9826J
Benchmark Holdings PLC
03 May 2022
3 May 2022
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Ectosan(R) Vet
Variation to Marketing Authorisation enabling a second use of
treatment water
An important milestone towards optimal efficiency of Benchmark's
transformational sea lice solution
Benchmark (LSE: BMK), the aquaculture biotechnology company, is
pleased to announce that it has been granted a variation to its
Marketing Authorisation ("MA") for Ectosan(R) Vet from the
Norwegian Medicines Agency ("NoMA").
This variation to the MA enables the re-use of the treatment
water for a second batch of fish, subject to water quality being
maintained to the satisfaction of the prescribing veterinarian,
therefore increasing the efficiency of treatments. This means a
producer will be able to treat a salmon farm more efficiently with
a solution that delivers more than 99% efficacy, promotes animal
welfare, reduces mortality and protects the environment - driving
sustainability in the industry.
This MA variation represents a further important step towards
our goal of optimising the efficiency of our sea lice solution, and
further trials are ongoing to support multiple re-use of treatment
water.
Trond Williksen, CEO, commented:
"We are very pleased to have been granted a variation to the
Marketing Authorisation from the Norwegian Medicines Agency. This
represents an important milestone for the Company and for the
industry. Ectosan(R) Vet and CleanTreat(R) is a much needed
solution for the industry which continues to show excellent results
with efficacy above 99% as well as good operational efficiency. It
is the first medicinal solution brought to the Norwegian market in
over ten years which addresses one of the biggest challenges in
salmon production, while improving animal welfare, reducing
mortality and protecting the environment."
Enquiries:
Benchmark Holdings plc Tel: 020 3696 0630
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black / Freddie Barnfield / Duncan
Monteith
MHP
Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd Tel: 020 3128 8990
benchmark@mhpc.com
About Benchmark
Benchmark is a market leading aquaculture biotechnology company.
Benchmark's mission is to drive sustainability in aquaculture by
delivering products and solutions in genetics, advanced nutrition
and health which improve yield, growth and animal health and
welfare.
Through a global footprint in 26 countries and a broad portfolio
of products and solutions, Benchmark addresses the major
aquaculture species - salmon, shrimp, sea bass and bream, and
tilapia, in all the aquaculture regions around the world. Find out
more at www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBLLLBLELZBBL
(END) Dow Jones Newswires
May 03, 2022 02:01 ET (06:01 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Jul 2023 to Jul 2024